💊Dapirolizumab (DZP) is a novel CD40L inhibitor 💊Results from phase 3 trial in #SLE 💊Demonstrated improvement i
Tweet Content
💊Dapirolizumab (DZP) is a novel CD40L inhibitor
💊Results from phase 3 trial in #SLE
💊Demonstrated improvement in disease activity & GC tapering
💊More pts on DZP achieved BICLA response vs PBO
💊DZP well tolerated
AbL16 #ACR24 @RheumNow https://t.co/dtb8QFKvlN
Links
Show on Archive Page
On
Display in Search Results
On
PDQ
Off